Avanir Pharmaceuticals clinical trials
Acquired by Otsuka Holdings Co., Ltd., Jan 13, 2015 · source ↗
The registry lists 13 studies whose lead sponsor is Avanir Pharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 29, 2022.
Before and after it joined Otsuka Holdings Co., Ltd.
- First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- 11
- First submitted after Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Avanir Pharmaceuticals13 studies
Something wrong with this grouping? Tell us on the Otsuka Holdings Co., Ltd. page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All Otsuka Holdings Co., Ltd. studies →
- Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease PatientsCompletedNCT01767129Phase 2
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's DiseaseCompletedNCT01584440Phase 2
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple SclerosisCompletedNCT01324232Phase 2
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult ParticipantsCompletedNCT03381664Phase 1
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted after Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)TerminatedNCT02496039Phase 4
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted after Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety and Efficacy of AVP-923 in PBA Patients With ALS or MSCompletedNCT00573443Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without AuraCompletedNCT01667679Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)CompletedNCT01799941Phase 4
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic NeuropathyCompletedNCT00113620Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)CompletedNCT00056524Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis PatientsCompletedNCT00050232Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALSCompletedNCT00021697Phase 3
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.
- PRISM Registry: Pseudobulbar Affect Registry SeriesCompletedNCT01366027
Sponsor listed in the registry: Avanir Pharmaceuticals · First submitted before Avanir Pharmaceuticals became part of Otsuka Holdings Co., Ltd.